ReviewThe Journal of clinical and aesthetic dermatology2026
Efficacy and Safety of Tildrakizumab in Elderly Patients With Psoriasis: A Narrative Review.
Review in The Journal of clinical and aesthetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTildrakizumab is an anti-interleukin 23 p19 monoclonal antibody approved for the treatment of adults with moderate-to-severe plaque psoriasis. Globally, patients aged ≥65 years are 9.8% to 12.8% of patients with psoriasis who are treated with biologics, but they are often underrepresented in clinical trials.
objectiveTo summarize the available evidence on the efficacy and safety of tildrakizumab in patients aged ≥65 years with psoriasis for a United States (US)-based healthcare practitioners audience.
methodsA PubMed search was conducted using the search terms "(tildrakizumab OR MK-3222 OR Ilumya) AND psoriasis AND (elderly OR 65 years)" to identify English-language clinical trials and real-world studies evaluating efficacy and safety of tildrakizumab in elderly patients with psoriasis.
resultsTwo clinical trials and 5 real-world studies describing the efficacy and safety of tildrakizumab in patients aged ≥65 years were identified. The short- and long-term efficacy of tildrakizumab was comparable between patients aged <65 and ≥65 years. Adverse events were consistent with those observed among the overall clinical trial population, with some expected increases in age-related events. LIMITATIONS: The number of studies with data for patients aged ≥65 years, and sample sizes within some studies, were small, limiting interpretation.
conclusionBased on available data, the established efficacy and safety profiles of tildrakizumab are maintained in patients aged ≥65 years with moderate-to-severe plaque psoriasis. Practical considerations, including insurance coverage, quarterly maintenance dosing, and in-office administration, in the US may increase treatment adherence and make tildrakizumab an appropriate treatment option for elderly patients.
Indexed as
Identifiers
42459247PMC13372309What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.